Veru Inc.
VERU
Rank in Stocks
#23943
Veru Inc. operates as a biopharmaceutical firm primarily dedicated to advancing... Veru Inc. operates as a biopharmaceutical firm primarily dedicated to advancing novel therapeutic agents for various types of cancer. Commercially, Veru markets the FC2 internal condom, designed to offer dual protection against both unplanned pregnancies and the transmission of sexually transmitted infections. This product is distributed globally to a diverse clientele, including governmental health departments, UN organizations, non-profit entities, and commercial distributors. Its robust development pipeline features a range of investigational therapies, notably within oncology: Enobosarm, an orally administered selective androgen receptor agonist, is progressing through Phase III clinical trials for treating metastatic breast cancer that is AR+, ER+, and HER2-negative. Sabizabulin is undergoing Phase IIb studies for the same type of metastatic breast cancer. Furthermore, a combination therapy of Enobosarm with abemaciclib is in Phase III for AR+ ER+ HER2- metastatic breast cancer. For metastatic triple-negative breast cancer, Veru is exploring a combination of Sabizabulin (an oral targeted cytoskeleton disruptor) and Enobosarm (a selective androgen receptor agonist) in Phase II trials. The company's portfolio also extends to prostate cancer: Sabizabulin is in Phase II trials for metastatic castration and androgen receptor targeting agent-resistant prostate cancer. VERU-100, a GnRH antagonist peptide delivered via injection, is also in Phase II for advanced hormone-sensitive prostate cancer. Beyond oncology, Veru is investigating other conditions: Zuclomiphene Citrate is in Phase II for managing hot flashes. Sabizabulin has reached Phase III for treating SARS-CoV-2 in high-risk patients susceptible to acute respiratory distress syndrome. Additionally, the firm is developing a novel pharmaceutical formulation aimed at alleviating lower urinary tract symptoms associated with an enlarged prostate in men. Originally established as The Female Health Company in 1971, the corporation adopted the name Veru Inc. in July 2017. Its corporate headquarters are situated in Miami, Florida.
Share Price
$2.19
Last synced: 2026-11-09
Market Cap
$37.34M
Change (1 day)
3.30%
Change (1 year)
-16.41%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Veru Inc. (VERU)
Category
Healthcare
Operating Margin for Veru Inc. (VERU)
Operating Margin as of November 2026 TTM: 0.00%
According to Veru Inc.'s latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2025 the company had an operating margin of 0.00%.
Operating Margin history for Veru Inc. from 2000 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2025 | 0.00% | -100.00% |
| 2024 | -218.61% | -62.01% |
| 2023 | -575.46% | 172.12% |
| 2022 | -211.47% | -1,098.44% |
| 2021 | 21.18% | -161.18% |
| 2020 | -34.62% | 71.05% |
| 2019 | -20.24% | -84.62% |
| 2018 | -131.57% | 111.53% |
| 2017 | -62.20% | -556.01% |
| 2016 | 13.64% | -32.81% |
| 2015 | 20.30% | 26.72% |
| 2014 | 16.02% | -48.52% |
| 2013 | 31.12% | -0.35% |
| 2012 | 31.23% | 75.94% |
| 2011 | 17.75% | -9.30% |
| 2010 | 19.57% | 14.24% |
| 2009 | 17.13% | 37.92% |
| 2008 | 12.42% | 174.17% |
| 2007 | 4.53% | 179.63% |
| 2006 | 1.62% | -113.79% |
| 2005 | -11.75% | -2.81% |
| 2004 | -12.09% | -18.09% |
| 2003 | -14.76% | -53.47% |
| 2002 | -31.72% | 253.23% |
| 2001 | -8.98% | -80.37% |
| 2000 | -45.75% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | - |
US
|
|
| -149.01% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 31.23% | - |
BE
|
|
| 29.35% | - |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Veru Inc.'s operating margin
What was Veru Inc.'s operating margin in 2025?
In 2025, Veru Inc.'s operating margin was 0.00%, compared with -218.61% in 2024.
How has Veru Inc.'s operating margin changed since 2020?
From 2020 to 2025, Veru Inc.'s operating margin was highest in 2021 (21.18%) and lowest in 2023 (-575.46%).
How does Veru Inc.'s operating margin compare with similar companies?
Veru Inc.'s operating margin (0.00%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.